Asahi Kasei Pharma Corp. has acquired Artisan Pharma, Inc., establishing a wholly-owned subsidiary, Asahi Kasei Pharma America Corp. (AKP America). The transaction establishes a U.S. presence for Asahi Kasei Pharma and provides access to the global development and commercialization of ART-123 (recombinant human thrombomodulin alpha, marketed as Recomodulin in Japan) in severe sepsis patients with coagulopathy. Asahi Kasei Pharma established Artisan Pharma in 2006 with several venture capital fir...